SonoCloud®

About CarThera

CarThera is pioneering a novel approach to treating severe brain diseases by using its proprietary SonoCloud® implantable ultrasound device to temporarily and reversibly open the blood-brain barrier, thereby increasing drug concentration in the brain. The company's lead program is in a pivotal trial (SONOBIRD) for recurrent glioblastoma, with a pipeline exploring applications in brain metastases and neurodegenerative diseases. Backed by four venture capital funds and led by a team of specialists, CarThera is advancing its technology through key clinical trials and strategic partnerships with international pharmaceutical companies.

About CarThera

CarThera is pioneering a novel approach to treating severe brain diseases by using its proprietary SonoCloud® implantable ultrasound device to temporarily and reversibly open the blood-brain barrier, thereby increasing drug concentration in the brain. The company's lead program is in a pivotal trial (SONOBIRD) for recurrent glioblastoma, with a pipeline exploring applications in brain metastases and neurodegenerative diseases. Backed by four venture capital funds and led by a team of specialists, CarThera is advancing its technology through key clinical trials and strategic partnerships with international pharmaceutical companies.

About CarThera

CarThera is pioneering a novel approach to treating severe brain diseases by using its proprietary SonoCloud® implantable ultrasound device to temporarily and reversibly open the blood-brain barrier, thereby increasing drug concentration in the brain. The company's lead program is in a pivotal trial (SONOBIRD) for recurrent glioblastoma, with a pipeline exploring applications in brain metastases and neurodegenerative diseases. Backed by four venture capital funds and led by a team of specialists, CarThera is advancing its technology through key clinical trials and strategic partnerships with international pharmaceutical companies.

Therapeutic Areas